Title |
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification
|
Institution |
DUKE UNIVERSITY, DURHAM, NC
|
Principal Investigator |
WHITE, REBEKAH
|
NCI Program Director |
White
|
Cancer Activity |
Early Detection - Biomarkers
|
Division |
DCP
|
Funded Amount |
$207,495
|
Project Dates |
09/01/2015 - 08/31/2017
|
Fiscal Year |
2015
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Digestive Diseases (100.0%)
|
Pancreas (100.0%)
|
Research Type |
Technology Development and/or Marker Discovery
|
Abstract |
DESCRIPTION (provided by applicant): The symptoms of pancreatic cancer are usually non-specific and late. Existing blood tumor biomarkers, such as carbohydrate antigen 19-9 (CA19-9), are not sensitive and specific enough to serve as useful screening tests. Tools for earlier detection could increase the proportion of patients who are diagnosed at early stages and potentially cured with surgical resection. Aptamers are oligonucleotide (RNA or DNA) molecules that directly bind to proteins with high specificity and can be used for the dual purpose of identifying novel biomarkers and detecting them in body fluids. We used a novel selection method (known as secretome selection) to identify aptamers that bind to proteins that are secreted by cultured pancreatic cancer cells but not to those secreted by non-cancerous pancreatic cells. One winning aptamer from this selection binds Cyclophilin B (CypB), a protein that has not previously been investigated as a blood biomarker for pancreatic cancer. We have demonstrated that CypB serum levels discriminate well between pancreatic cancer patients and healthy volunteers but not as well between patients with pancreatic cancer and patients with benign pancreatic disease. Our primary hypothesis is that a similar positive/negative aptamer selection strategy can be applied to serum samples from patients with pancreatic cancer and benign pancreatic disease to identify novel serum biomarkers that are specific for pancreatic cancer. The specific aims of this project are: 1) To identify additional pancreatic cancer biomarkers using an aptamer selection strategy applied to blood samples from human patients. 2) To develop assays based on these selected aptamers (including the CypB aptamer) that could be used clinically for the detection of blood biomarkers. 3) To retrospectively evaluate whether these candidate biomarkers can distinguish between patients with early pancreatic cancer, patients with benign pancreatic diseases, and unaffected patients. The successful completion of this project will lead to the identification of new biomarkers that may be useful for the diagnosis, staging, and/or treatment of pancreatic cancer. Moreover, this approach to biomarker selection can be generalized to other cancers for which better biomarkers are needed. " |